Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run.
New features include an electronics design to improve system performance, reliability, and stability. The improved software is said to offer a more advanced and reliable system to help further simplify antibody discovery, cell line development, cell therapy, and synthetic biology workflows.
Dr. Marian Rehak, VP of Research and Development at Sphere Fluidics, said: “The new design is the culmination of 18 months’ hard work by our R&D team. Due to the deployment of these latest improvements, researchers are now able to perform even faster selective screening of single cells to find rare lead candidates. Although, principally designed for antibody discovery and cell line development, the platform is very flexible and has now been demonstrated to be useful in a wide variety of application areas.”